Boehringer Ingelheim
For Healthcare Professionals

Shorts

See all  >
Read more
Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?

Upcoming Events

See all  >

Past Events

See all  >

Resources

Did you find what you were looking for?

Your feedback submitted Successfully !